A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Acumen Pharmaceuticals, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 2,900 shares of ABOS stock, worth $5,133. This represents 0.0% of its overall portfolio holdings.

Number of Shares
2,900
Previous 4,000 27.5%
Holding current value
$5,133
Previous $9,000 22.22%
% of portfolio
0.0%
Previous 0.0%

Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$2.22 - $3.54 $146,742 - $233,994
-66,100 Reduced 79.63%
16,912 $41,000
Q2 2024

Aug 14, 2024

BUY
$2.14 - $4.01 $127,674 - $239,240
59,661 Added 255.5%
83,012 $200,000
Q1 2024

May 15, 2024

SELL
$2.97 - $4.64 $320,062 - $500,029
-107,765 Reduced 82.19%
23,351 $94,000
Q4 2023

Feb 14, 2024

BUY
$1.86 - $4.48 $243,444 - $586,360
130,884 Added 56415.52%
131,116 $503,000
Q3 2023

Nov 14, 2023

SELL
$4.15 - $9.72 $195,722 - $458,414
-47,162 Reduced 99.51%
232 $0
Q2 2023

Aug 14, 2023

BUY
$3.59 - $6.59 $119,593 - $219,532
33,313 Added 236.58%
47,394 $227,000
Q1 2023

May 15, 2023

BUY
$3.75 - $6.65 $52,803 - $93,638
14,081 New
14,081 $57,000

Others Institutions Holding ABOS

About Acumen Pharmaceuticals, Inc.


  • Ticker ABOS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 40,503,100
  • Market Cap $71.7M
  • Description
  • Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Ph...
More about ABOS
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.